Lung cancer treatment has evolved significantly over the years, offering patients different options depending on the type and stage of their disease. Radiotherapy remains an important part of treatment for many patients, particularly when surgery is not suitable or radiation is needed alongside other therapies.
One of the developments in radiation treatment is proton therapy, which uses a different type of radiation from conventional X-ray treatment.
But how does proton therapy work, and can it offer advantages for people with lung cancer?
Understanding the differences can help patients and caregivers have more informed discussions with their treating doctors.
Lung Cancer in India: Why Treatment Awareness Matters
Lung cancer is a major health concern in India. According to the Indian Council of Medical Research’s National Cancer Registry Programme, an estimated 1,03,371 new lung cancer cases occurred in India in 2022, highlighting the importance of awareness and access to appropriate cancer care.
Although smoking is a major risk factor, lung cancer can also affect people who have never smoked.
Treatment depends on several factors, including the type of lung cancer, its stage, the patient’s overall health and the tumour’s characteristics.
Depending on these factors, doctors may recommend surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy or a combination of treatments.
What Is Proton Therapy for Lung Cancer?
Proton therapy, also known as proton beam therapy, is a type of external-beam radiotherapy that uses charged particles called protons to treat cancer.
Conventional radiotherapy generally uses high-energy X-rays, also called photons.
Both treatments aim to damage cancer cells while limiting radiation exposure to surrounding healthy tissues.
The main difference is how they deliver radiation within the body.
X-rays deposit radiation energy as they travel through tissues, including beyond the tumour. Proton beams can be planned to release much of their energy at a selected depth, potentially reducing radiation exposure beyond the treatment target.
This physical characteristic may be useful when a tumour is located close to sensitive organs.
However, proton therapy does not completely prevent radiation exposure to healthy tissues, and its advantages vary from patient to patient.
How Is Proton Therapy Different from Conventional Radiotherapy?
Modern conventional radiotherapy techniques, including intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT), can deliver highly targeted treatment.
Proton therapy offers another way to shape the radiation dose.
For some patients, a proton treatment plan may reduce the radiation reaching nearby healthy tissues compared with an optimised X-ray treatment plan.
However, this does not mean proton therapy is always the better option.
Doctors must consider how effectively each treatment covers the tumour, how much radiation reaches surrounding organs and whether the plan can be delivered reliably.
The most appropriate treatment is the one that offers a suitable balance of expected effectiveness, potential risks and individual patient needs.
What Are the Potential Benefits of Proton Therapy for Lung Cancer?
The potential advantage of proton therapy lies primarily in how radiation can be distributed within the body.
In selected patients, it may offer the following treatment-planning benefits.
Reduced Radiation Exposure to Healthy Lung Tissue
Proton therapy may reduce the amount of radiation reaching certain areas of healthy lung tissue.
This can be relevant because radiation-related lung inflammation is one of the possible complications of radiotherapy to the chest.
However, a lower planned radiation dose does not automatically mean a lower risk of complications.
Limiting Radiation Exposure to Nearby Organs
The lungs are surrounded by important structures, including the heart, oesophagus and spinal cord.
Depending on the tumour’s location, proton treatment planning may reduce radiation exposure to some of these structures.
The extent of this advantage depends on the individual patient’s anatomy and treatment plan.
An Option in Selected Complex Cases
Proton therapy may also be considered when a tumour is close to sensitive organs or when a patient has previously received radiation to the chest.
Such situations require careful assessment by an experienced radiation oncology team.
These are potential planning advantages, not guaranteed improvements in survival, tumour control or quality of life.
Does Proton Therapy Improve Lung Cancer Treatment Outcomes?
Proton therapy may reduce radiation exposure to certain healthy tissues, but whether this leads to better treatment outcomes depends on the individual patient and clinical situation.
A systematic review published in Cancers in January 2026 compared proton and photon radiotherapy for non-small cell lung cancer. The pooled results did not establish a statistically significant overall survival advantage or a consistent reduction in radiation-related lung inflammation with proton therapy.
Although some studies suggest potential benefits in selected patients, further research is needed to understand where proton therapy offers the greatest clinical value.
For this reason, proton therapy should not be viewed as universally superior to modern conventional radiotherapy. Treatment decisions should be based on the patient’s condition, comparative radiation plans and available clinical evidence.
Why Is Breathing Motion Important During Proton Therapy?
Lung tumours can move as a person breathes.
This movement can affect how radiation reaches the intended treatment area.
Proton beams are particularly sensitive to changes in tissue position and density, making accurate imaging and treatment planning essential.
Specialist teams may use breathing assessments, imaging techniques and treatment verification methods to help account for movement.
These precautions are important for delivering an appropriate radiation dose while managing treatment uncertainties.
Who May Be Considered for Proton Therapy?
Proton therapy is not necessary or suitable for every person with lung cancer.
A radiation oncologist may consider evaluating a proton treatment plan in selected circumstances, such as:
- Tumours located close to sensitive organs.
- Cases where conventional radiation planning is particularly challenging.
- Selected patients who have previously received radiotherapy to the chest.
- Situations where proton planning may provide a meaningful reduction in radiation exposure to healthy tissue.
The decision depends on cancer type and stage, treatment goals, tumour location, previous treatment, overall health and specialist assessment.
Doctors may compare proton and conventional radiotherapy plans to determine whether proton therapy offers a clinically meaningful advantage.
Availability, treatment access and cost may also influence the options patients can consider.
Frequently Asked Questions About Proton Therapy for Lung Cancer
1. Is proton therapy safer than conventional radiotherapy?
Proton therapy may reduce radiation exposure to certain healthy tissues in selected patients. However, this does not guarantee fewer side effects, and it has not been shown to be safer for every lung cancer patient.
2. Is proton therapy more effective for lung cancer?
Current evidence has not established that proton therapy consistently provides better long-term survival or tumour control than modern conventional radiotherapy across all lung cancer patients. Some findings suggest possible benefits in specific settings, but further research is needed.
3. Can proton therapy be used after previous lung radiation treatment?
It may be considered in selected patients who require another course of radiation. These situations need careful specialist assessment because previous radiation exposure increases the complexity and risks of treatment.
4. Is proton therapy available in India?
Proton therapy is available at selected centres in India. However, availability does not mean it is appropriate for every lung cancer patient. Treatment suitability should be determined through specialist assessment.
Conclusion: Choosing the Right Radiation Treatment
Proton therapy represents an important development in radiation treatment, with the potential to reduce radiation exposure to selected healthy tissues in certain lung cancer patients.
However, the best treatment is not determined by technology alone. It depends on the patient’s condition, tumour characteristics, available clinical evidence and careful treatment planning.
For patients and caregivers, understanding the potential benefits and limitations of proton therapy can support more informed conversations with their radiation oncologist.
Through its collaboration with TecAustron, Weembrace Biopharma supports scientific awareness and informed discussions about particle therapy and its evolving role in cancer care.
References and Further Reading
- Indian Council of Medical Research – National Cancer Registry Programme. Cancer Incidence Estimates for 2022 and Projection for 2025: Results from the National Cancer Registry Programme, India. Indian Journal of Medical Research.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10231735/ - National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®) – Health Professional Version.
https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq - Fang CC, Chen WC, Tsai MS, Chen MF. Proton Versus Photon Radiotherapy for Non-Small Cell Lung Cancer: Updated Evidence from a Systematic Review and Meta-Analysis. Cancers. 2026;18(3):453.
https://doi.org/10.3390/cancers18030453 - NRG Oncology. RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Non-Small Cell Lung Cancer. Clinical trial information.
https://www.nrgoncology.org/Clinical-Trials/Protocol/rtog-1308/
Medical Disclaimer
This article is intended for general educational and informational purposes only. It does not replace professional medical advice, diagnosis or treatment. The suitability of proton therapy or any other lung cancer treatment depends on individual clinical circumstances and should be determined in consultation with a qualified oncology specialist.
